Carcinoma, hepatocellular Trials in Guangzhou, China
Conditions / Carcinoma, hepatocellular / Guangzhou, China
Carcinoma, hepatocellular is a medical condition with active clinical research programs worldwide.
32 total trials for this combination
Showing top 10 of 32 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03713593 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | COMPLETED | PHASE3 |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | COMPLETED | — |
| NCT01009593 | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | TERMINATED | PHASE3 |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma | COMPLETED | PHASE3 |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | COMPLETED | PHASE3 |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | COMPLETED | — |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | COMPLETED | — |
| NCT01774344 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma | COMPLETED | PHASE3 |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | COMPLETED | — |